Brief: IRLAB Says Mesdopetam Could Prevent Dyskinesia In Parkinson's

IRLAB Therapeutics AB

11/01/2021 08:33

Jan 11 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB PRESENTS NEW DATA INDICATING THAT MESDOPETAM COULD
PREVENT
DYSKINESIA IN PARKINSON'S DISEASE
    * OBTAINED NEW RESULTS FROM PRECLINICAL STUDIES WHICH
INDICATE
THAT DRUG CANDIDATE MESDOPETAM ALSO HAS POTENTIAL TO PREVENT
DEVELOPMENT OF LEVODOPA-INDUCED DYSKINESIAS, INVOLUNTARY AND
TROUBLESOME MOVEMENTS, IN PARKINSON'S DISEASE
    * COMPOUND HAS PREVIOUSLY BEEN SHOWN EFFICACIOUS IN
TREATMENT OF
ALREADY ESTABLISHED DYSKINESIA, WHICH IS FURTHER STUDIED IN AN
ONGOING PHASE IIB/III STUDY
    * IN STUDY, AMANTADINE, CURRENT TREATMENT OPTION FOR
LEVODOPA
INDUCED DYSKINESIA, WAS ALSO STUDIED BUT DID NOT SHOW SAME
SUPPRESSION OF SENSITIZATION TO LEVODOPA

Source text for Eikon:  ID:nWkr5PFNYy 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))